X4 Pharmaceuticals, INC 8-K filings

X4 Pharmaceuticals has appointed Kelly Gold, an experienced CFO, to its Board of Directors, effective July 1, 2026, to enhance strategic and financial expertise.

X4 Pharmaceuticals filed an amendment to its 8-K to correct a typographical error regarding a director nominee.

X4 Pharmaceuticals, Inc. announced the results of its annual stockholder meeting, including the election of directors, ratification of its auditor, and approval of an amended equity incentive plan.

X4 Pharmaceuticals announced Q3 2025 financial results, a strategic shift to chronic neutropenia, significant cost savings, and extended cash runway.

X4 Pharmaceuticals successfully completed a public offering of common stock and pre-funded warrants, raising approximately $145.6 million to fund its operations.

X4 Pharmaceuticals announced a strategic restructuring, including a 50% workforce reduction, to sharpen operational focus and align resources with its long-term strategy.

X4 Pharmaceuticals announced the immediate resignations of two directors and subsequent appointments to its Audit Committee, effective August 22, 2025.

X4 Pharmaceuticals successfully closed an upsized $85 million private placement to fund clinical trials and commercialization efforts.

X4 Pharmaceuticals announced a $60 million private placement financing and a significant overhaul of its executive team and board leadership, effective August 12, 2025.

X4 Pharmaceuticals, Inc. has entered into a purchase agreement with Lincoln Park Capital Fund, LLC, providing the company with the right to sell up to $40 million of its common stock over a 24-month period.

X4 Pharmaceuticals Inc. announced that its stockholders approved all proposals at the Annual Meeting held on June 9, 2025, including the election of R. Keith Woods as director, the ratification of PricewaterhouseCoopers LLP as independent auditor, and the non-binding advisory vote on executive compensation.

X4 Pharmaceuticals announces Q1 2025 financial results, highlighting progress in clinical trials, commercialization of XOLREMDI, and strategic partnerships.

X4 Pharmaceuticals implements a 1-for-30 reverse stock split, effective April 28, 2025, to increase its stock price and regain compliance with Nasdaq listing requirements.

X4 Pharmaceuticals' stockholders approved a reverse stock split proposal at a special meeting held on April 17, 2025.

X4 Pharmaceuticals announces its Q4 and full year 2024 financial results, highlighting progress with XOLREMDI and the 4WARD trial in chronic neutropenia.

X4 Pharmaceuticals has been granted a second extension by Nasdaq to regain compliance with the minimum bid price rule, setting a new deadline of August 11, 2025.

X4 Pharmaceuticals is restructuring its operations to prioritize mavorixafor development for chronic neutropenia and optimize XOLREMDI promotion, resulting in workforce reductions and cost savings.

X4 Pharmaceuticals has partnered with Norgine to commercialize mavorixafor in Europe, Australia, and New Zealand, securing a $28.5 million upfront payment and potential for up to $226 million in milestone payments.

X4 Pharmaceuticals reports positive results from a Phase 2 trial of mavorixafor, showing increased neutrophil counts and reduced need for G-CSF in chronic neutropenia patients.

X4 Pharmaceuticals reported positive Phase 2 clinical trial results for mavorixafor in chronic neutropenia, along with updates on the U.S. launch of XOLREMDI and progress in the Phase 3 trial.

X4 Pharmaceuticals has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, putting its listing at risk.

X4 Pharmaceuticals has released an updated corporate presentation on its website, accessible through the investor relations section.

X4 Pharmaceuticals announced its second quarter 2024 financial results, highlighted by the first commercial sales of XOLREMDI and positive clinical trial updates.

X4 Pharmaceuticals has released an updated corporate presentation on its website, providing investors with the latest company information.

X4 Pharmaceuticals reported positive interim results from its Phase 2 trial of mavorixafor in chronic neutropenia, showing durable increases in neutrophil counts, and has initiated a pivotal Phase 3 trial.

X4 Pharmaceuticals held its annual meeting of stockholders on June 10, 2024, where directors were elected, the accounting firm was ratified, and executive compensation was approved in a non-binding vote.

X4 Pharmaceuticals is actively launching XOLREMDI for WHIM syndrome, while also advancing its pipeline with a Phase 3 trial for chronic neutropenia expected to begin in the second quarter of 2024.

X4 Pharmaceuticals has secured $125 million through the sale of a Priority Review Voucher and a loan drawdown, extending its cash runway into late 2025.

X4 Pharmaceuticals announced its first quarter 2024 financial results, highlighted by the U.S. launch of XOLREMDI for WHIM syndrome and upcoming clinical data presentations.

X4 Pharmaceuticals announced FDA approval and commercial launch of XOLREMDI for WHIM syndrome, along with a patient support program and pricing details.